Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 16 , ISSUE 5 ( September-October, 2024 ) > List of Articles

RESEARCH ARTICLE

Prediction of Assisted Reproductive Technology Outcome by Day 5 Estradiol (E2) Levels in Antagonist Cycles

Naga P Indrakanti, Anjali S Mudkur, Vidyashree G Poojari, Mehtab Kaur, Dhanya Vikhnan, Pratap K Narayan, Prashanth K Adiga

Keywords : Antagonist, Estradiol, M-II oocytes, Ovarian hyperstimulation syndrome

Citation Information : Indrakanti NP, Mudkur AS, Poojari VG, Kaur M, Vikhnan D, Narayan PK, Adiga PK. Prediction of Assisted Reproductive Technology Outcome by Day 5 Estradiol (E2) Levels in Antagonist Cycles. J South Asian Feder Obs Gynae 2024; 16 (5):542-545.

DOI: 10.5005/jp-journals-10006-2507

License: CC BY-NC 4.0

Published Online: 23-10-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Aim and background: Follicle monitoring and hormone levels, particularly those of estradiol (E2), progesterone (P4), follicle-stimulating hormone (FSH), and luteinizing hormone, are critical factors in determining the effectiveness of in vitro fertilization (IVF). Based on their day-5 E2 readings, patients are divided into three groups. Group I comprises values less than 400 pg/mL, group II ranges from 400 to 900 pg/mL, and group III exceeds 900 pg/mL. The study's objectives were to construct a prediction formula for the total number of retrieved oocytes, analyze the mean number of mature and total oocytes, and determine the incidence of ovarian hyperstimulation syndrome (OHSS) in three groups. Materials and methods: The Department of Reproductive Medicine and Surgery at a tertiary care facility in coastal Karnataka carried out this retrospective observational research. The study included 140 patients who underwent IVF stimulation using the antagonist protocol between May 2022 and April 2023, a duration of 1 year. Simple linear regression techniques and receiver operating curve (ROC) curves are utilized in statistical analysis. Results: The average age, duration of infertility, BMI, antral follicle count (AFC), and anti-mullerian hormone (AMH) were in that order 31.51 years, 5.04 years, 24.44 kg/m2, 17.67, and 3.63 ng/mL. Based on the day 5 E2 values and the difference between the day 5 and the trigger E2 values, the quantity and mature oocytes were predicted with statistical significance. The E2 threshold levels on day 5 and the day of trigger to day 5 E2 difference were 946 pg/mL and 2758 pg/mL, respectively, to forecast and prevent OHSS. Conclusion: The current study's measurement of the day-5 E2 level is significant since it aids in the prediction of the number and maturity of oocytes as well as the risk of OHSS.


PDF Share
  1. The ESHRE guideline group on ovarian stimulation, Bosch E, Broer S, et al. Erratum: ESHRE guideline: Ovarian stimulation for IVF/ICSI. Hum Reprod Open 2020;2020:hoaa067. DOI: 10.1093/hropen/hoaa067.
  2. Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;(5):CD001750. DOI: 10.1002/14651858.CD001750.pub3.
  3. Wang Y, Xu X, Yang AM, et al. Optimizing estradiol level for gonadotrophin-releasing hormone antagonist initiation among patients with simple tubal factor infertility. Front Endocrinol (Lausanne) 2022;13:915923. DOI: 10.3389/fendo.2022.915923.
  4. Khalaf Y, Taylor A, Braude P. Low serum estradiol concentrations after five days of controlled ovarian hyperstimulation for in vitro fertilization are associated with poor outcome. Fertil Steril 2000;74(1):63–66. DOI: 10.1016/S0015-0282(00)00569-0.
  5. El Maghraby HA, Mahdi M, El Arab MS, et al. Stimulation day-six serum estradiol: A predictive indicator for the probability of embryo cryopreservation in IVF/ICSI cycles. J Obstet Gynaecol Res 2009;35(2):326–329. DOI: 10.1111/j.1447-0756.2008.00940.x.
  6. Wei CX, Zhang L, Pang CH, et al. Effect of the ratios of estradiol increase on the outcome of in vitro fertilization-embryo transfer with antagonist regimens: A single center retrospective cohort study. BMC Pregnancy Childbirth 2023;23(1):134. DOI: 10.1186/s12884-023-05438-3.
  7. Wertheimer A, Danieli-Gruber S, Hochberg A, et al. The association between treatment parameters on the day of gonadotropin- releasing hormone antagonist initiation during a flexible protocol and oocyte maturation rate. Reprod Biol 2020;20:127–131. DOI: 10.1016/j.repbio.2020.04.004.
  8. Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85(1):112–120. DOI: 10.1016/j.fertnstert.2005.07.1292.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.